09.02.2021 • NewsAkzoNobelPPGTikkurila

AkzoNobel Walks Away from Tikkurila

AkzoNobel has conceded defeat in its bid to buy Tikkurila, leaving the way clear for US rival PPG Industries to continue with its acquisition of the Finnish paints and coatings company.

In a statement issued on Feb. 8, the Dutch group said it no longer intends to pursue the acquisition. “Despite a cultural fit – and more synergies than any other combination with Tikkurila – the intended transaction no longer meets AkzoNobel’s criteria for superior value creation,” the company stated.

“We have clear priorities and criteria for capital allocation, including investing for growth, paying dividends, conducting acquisitions and carrying out share buybacks,” said AkzoNobel CEO Thierry Vanlancker. “Executing with discipline has been key to AkzoNobel’s transformation into a company with higher profitability and strong free cash flow. This is working well for us and part of who we are.”

The Amsterdam-headquartered group offered about €1.4 billion for Tikkurila on 18 Jan, forcing PPG to raise its bid of about €1.24 billion to the final agreed price of approximately €1.52 billion. PPG is expecting to close on the acquisition either in March or early in the second quarter.

Author: Ellaine Burridge, Freelance Journalist

AkzoNobel has conceded defeat in its bid to buy Tikkurila, leaving the way...
AkzoNobel has conceded defeat in its bid to buy Tikkurila, leaving the way clear for US rival PPG to continue with its acquisition of the Finnish paints and coatings company. The Dutch group said the intended transaction no longer meets its criteria for superior value creation. (c) Tikkurila

Company

Logo:

AkzoNobel

Christian Neefestraat 2
1077 WW Amsterdam
Netherlands

Company contact







Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read